ANNEX I

SUMMARY OF PRODUCT CHARACTERISTICS

1. NAME OF THE MEDICINAL PRODUCT

EMADINE 0.5 mg/ml, eye drops, solution

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

1 ml of solution contains emedastine 0.5 mg (as difumarate)

Excipient with known effect

Benzalkonium chloride 0.1 mg/ml

For the full list of excipients, see section 6.1

3. PHARMACEUTICAL FORM

Eye drops, solution.

Clear, colourless solution.

4. CLINICAL PARTICULARS

4.1 Therapeutic indications

Symptomatic treatment of seasonal allergic conjunctivitis.

4.2 Posology and method of administration

EMADINE has not been studied in clinical trials beyond six weeks.

Posology

The dose is one drop of EMADINE to be applied to the affected eye(s) twice daily.

When used with other ophthalmic medicines, an interval of ten minutes should be allowed between applications of each medicinal product. Eye ointments should be administered last.

Elderly population
EMADINE has not been studied in elderly patients older than 65 years, and therefore its use is not recommended in this population.

Paediatric population
EMADINE may be used in paediatric patients (3 years of age and older) at the same posology as in adults.

Hepatic and Renal impairment Use
EMADINE has not been studied in these patients and therefore, its use is not recommended in this population.

Method of administration

For ocular use.

To prevent contamination of the dropper tip and solution, care should be taken not to touch the eyelids, surrounding areas or other surfaces with the dropper tip of the bottle.

After cap is removed, if tamper evident snap collar is loose, remove before using product.

4.3 Contraindications

Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

4.4 Special warnings and precautions for use

Ocular corneal infiltrates

Ocular corneal infiltrates were reported in conjunction with the use of EMADINE. In case of corneal infiltrates, the product should be discontinued and appropriate management should be implemented.

Excipients

Benzalkonium chloride, which is commonly used as a preservative in ophthalmic products, has been reported to cause punctate keratopathy and/or toxic ulcerative keratopathy. Since EMADINE contains benzalkonium chloride, close monitoring is required with frequent or prolonged use.

In addition benzalkonium chloride may cause eye irritation and is known to discolour soft contact lenses. Contact with soft contact lenses is to be avoided. Patients must be instructed to remove contact lenses prior to the application of EMADINE and wait 15 minutes after instillation of the dose before reinsertion.

4.5 Interaction with other medicinal products and other forms of interaction

No interaction studies have been performed.

4.6 Fertility, pregnancy and lactation

Pregnancy

There are no adequate data from the use of emedastine in pregnant women. Studies in animals have shown reproductive toxicity (see section 5.3). The potential risk for humans is unknown. Nevertheless, considering the absence of effects of emedastine on adrenergic, dopaminergic and serotonin receptors, EMADINE can be used during pregnancy if the dosage recommendation in section 4.2 is respected.

Breast-feeding

Emedastine has been identified in the milk of rats following oral administration. It is not known whether topical administration to humans could result in sufficient systemic absorption to produce detectable quantities in breast milk. Caution should be exercised if EMADINE is administered during breast-feeding.

Fertility

Studies in animals have shown no evidence of impaired fertility (See Section 5.3). No human fertility data are available.

4.7 Effects on ability to drive and use machines

EMADINE has no or negligible influence on the ability to drive and use machines, however as with any ocular medication, if transient blurred vision or other visual disturbance occurs at instillation, the patient should wait until the vision clears before driving or using machinery.

4.8 Undesirable effects

Summary of safety profile

In 13 clinical studies involving 696 patients, Emadine was administered one to four times daily in both eyes for up to 42 days. In clinical trials, approximately 7% of patients experienced an adverse drug reaction associated with the use of Emadine; however, less than 1% of these patients discontinued therapy due to these adverse drug reactions. No serious ophthalmic or systemic adverse drug reactions were reported in the clinical trials. The most common adverse drug reactions were eye pain and eye pruritus occurring in 1% to 2.0% of patients.

Tabulated list of adverse reactions

The following adverse reactions listed below were observed in clinical studies or with post marketing experience. They are ranked according to system organ class and classified according to the following convention: very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1000 to <1/100), rare (≥1/10,000 to <1/1000), very rare (<1/10,000), or not known (cannot be estimated from the available data). Within each frequency grouping, adverse reactions are presented in decreasing order of seriousness.

System Organ Classification	**Frequency**	**Adverse reaction**
Psychiatric disorders	Uncommon	abnormal dreams
Nervous system disorders	Uncommon	headache, sinus headache, dysgeusia
Eye disorders	Common	eye pain, eye pruritus, conjunctival hyperaemia
	Uncommon	corneal infiltrates, corneal staining, blurred vision, eye irritation, dry eye, foreign body sensation in eyes, lacrimation increased, asthenopia, ocular hyperaemia
Cardiac disorders	Not known	tachycardia
Skin and subcutaneous tissue disorders	Uncommon	rash

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in Appendix V.

4.9 Overdose

No specific reactions are to be expected with an ocular overdose of the product.

No data are available in humans regarding overdose by accidental or deliberate ingestion. In case of accidental ingestion of the content of a bottle of EMADINE, sedative effects may occur and the potential of emedastine to increase the QT interval should be borne in mind and appropriate monitoring and management should be implemented.

5. PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties

Pharmacotherapeutic group: decongestants and antiallergics; other antiallergics, ATC code: S01G X 06

Emedastine is a potent selective and topically effective histamine H_1 antagonist (K_i = 1.3 nM). *In vitro* examinations of emedastine's affinity for histamine receptors (H_1, H_2, and H_3) demonstrate 10,000-fold selectivity for the H_1 receptor, K_i's = 1.3 nM, 49,064 nM and 12, 430 nM, respectively. *In vivo* topical ocular administration of emedastine produces a concentration-dependent inhibition of histamine-stimulated conjunctival vascular permeability. Studies with emedastine have not shown effects on adrenergic, dopaminergic, and serotonin receptors.

5.2 Pharmacokinetic properties

Absorption

Emedastine is absorbed systemically, as are other topically administered drug substances. In a study involving ten normal volunteers dosed bilaterally twice daily for 15 days with EMADINE 0.5 mg/ml eye drops solution, plasma concentrations of the parent compound were generally below the quantitation limit of the assay (0.3 ng/ml). Samples in which emedastine was quantifiable ranged from 0.30 to 0.49 ng/ml.

The human oral bioavailability of emedastine is approximately 50% and maximum plasma concentrations were achieved within one-two hours after dosing.

Biotransformation

Emedastine is principally metabolised by the liver. The elimination half-life of topical emedastine is ten hours. Approximately 44% of an oral dose is recovered in the urine over 24 hours, with only 3.6% of the dose excreted as parent drug substance. Two primary metabolites, 5-and 6-hydroxyemedastine, are excreted in the urine as both free and conjugated forms. The 5′-oxo analogues of 5-and 6-hydroxyemedastine and the N-oxide are also formed as minor metabolites.

5.3 Preclinical Safety Data

Emedastine difumarate demonstrated low acute toxicity in a number of species by various routes of administration. No clinically significant local or systemic effects were observed in long-term topical ocular studies in rabbits.

Corneal limbal mononuclear cell infiltrates were noted in 1/4 male monkeys treated with 0.5 mg/ml and in 4/4 males and 1/4 females treated with1.0 mg/ml. Scleral mononuclear cell infiltrates were present in 1/4 males and 1/4 females treated with 0.5 mg/ml and in 2/4 males and 1/4 females treated with1.0 mg/ml. Mean peak plasma levels were approximately 1 ng/ml and 2 ng/ml for the 0.5 and 1.0 mg/ml treatments respectively.

Emedastine was found to increase the QT interval in dogs; the NOEL corresponds to levels 23-fold higher than those found in patients (7 ng/ml as compared with 0.3 ng/ml, i.e., the limit of detection for emedastine).

Emedastine difumarate was not found to be carcinogenic in studies in mice and rats. Emedastine difumarate was not genotoxic in a standard battery of *in vitro* and *in vivo* genotoxicity assays.

In a teratology study in rats, foetotoxic but not teratogenic effects were observed at the highest dose evaluated (140 mg/kg/day); no effects were observed at a lower level (40 mg/kg/day) which corresponds to an exposure well in excess of that produced by the therapeutic recommended dose. No reproductive toxicity was observed in a study in rabbits.

There was no evidence of impaired fertility or decreased reproductive capacity in rats administered oral dosages of Emedastine difumarate of up to 30 mg/kg/day.

6. PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Benzalkonium chloride 0.1 mg/ml
Trometamol
Sodium chloride
Hypromellose
Hydrochloric acid/sodium hydroxide (to adjust pH)
Purified water

6.2 Incompatibilities

Not applicable.

6.3 Shelf life

30 months.

EMADINE should not be used for longer than 4 weeks after first opening.

6.4 Special precautions for storage

Do not store above 25°C.

6.5 Nature and content of container

EMADINE is supplied in 5 ml and 10 ml opaque plastic DROP-TAINER bottles.
Not all pack sizes may be marketed.

6.6 Special precautions for disposal

No special requirements.

7. MARKETING AUTHORISATION HOLDER

Novartis Europharm Limited
Vista Building
Elm Park, Merrion Road
Dublin 4
Ireland

8. MARKETING AUTHORISATION NUMBERS

EU/1/98/095/001-2

9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

Date of first authorisation: 27 January 1999
Date of latest renewal: 13 January 2009

10. DATE OF REVISION OF THE TEXT

Detailed information on this medicinal product is available on the website of the European Medicines Agency http://www.ema.europa.eu.

1. NAME OF THE MEDICINAL PRODUCT

EMADINE 0.5 mg/ml eye drops, solution, single-dose container.

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

1 ml of solution contains emedastine 0.5 mg (as difumarate).

For the full list of excipients, see section 6.1.

3. PHARMACEUTICAL FORM

Eye drops, solution.

Clear, colourless solution.

4. CLINICAL PARTICULARS

4.1 Therapeutic indications

Symptomatic treatment of seasonal allergic conjunctivitis.

4.2 Posology and method of administration

EMADINE has not been studied in clinical trials beyond six weeks.

Posology

The dose is one drop of EMADINE to be applied to the affected eye(s) twice daily.

When used with other ophthalmic medicines, an interval of ten minutes should be allowed between applications of each medicinal product. Eye ointments should be administered last.

For single use only; one container is sufficient to treat both eyes. Any unused solution should be discarded immediately after use.

Elderly Population
EMADINE has not been studied in elderly patients older than 65 years, and therefore its use is not recommended in this population.

Paediatric Population
EMADINE may be used in paediatric patients (3 years of age and older) at the same posology as in adults.

Hepatic and Renal impairment Use
EMADINE has not been studied in these patients and therefore, its use is not recommended in this population.

Method of administration

For ocular use.

4.3 Contraindications

Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

4.4 Special warnings and precautions for use

Ocular corneal infiltrates

Ocular corneal infiltrates were reported in conjunction with the use of EMADINE. In case of corneal infiltrates, the product should be discontinued and appropriate management should be implemented.

4.5 Interaction with other medicinal products and other forms of interaction

No interaction studies have been performed.

4.6 Fertility, pregnancy and lactation

Pregnancy

There are no adequate data from the use of emedastine in pregnant women. Studies in animals have shown reproductive toxicity (see section 5.3). The potential risk for humans is unknown. Nevertheless, considering the absence of effects of emedastine on adrenergic, dopaminergic and serotonin receptors, EMADINE can be used during pregnancy if the dosage recommendation in section 4.2 is respected.

Breast-feeding

Emedastine has been identified in the milk of rats following oral administration. It is not known whether topical administration to humans could result in sufficient systemic absorption to produce detectable quantities in breast milk. Caution should be exercised if EMADINE is administered during breast-feeding.

Fertility

Studies in animals have shown no evidence of impaired fertility (See Section 5.3). No human fertility data are available.

4.7 Effects on ability to drive and use machines

EMADINE has no or negligible influence on the ability to drive and use machines, however as with any ocular medication, if transient blurred vision or other visual disturbance occurs at instillation, the patient should wait until the vision clears before driving or using machinery.

4.8 Undesirable effects

Summary of safety profile

In 13 clinical studies involving 696 patients, Emadine was administered one to four times daily in both eyes for up to 42 days. In clinical trials, approximately 7% of patients experienced an adverse drug reaction associated with the use of Emadine; however, less than 1% of these patients discontinued therapy due to these adverse drug reactions. No serious ophthalmic or systemic adverse drug reactions were reported in the clinical trials. The most common adverse drug reactions were eye pain and eye pruritus, occurring in 1% to of 2.0% of patients.

Tabulated list of adverse reactions

The following adverse reactions listed below were observed in clinical studies or with post marketing experience. They are ranked according to system organ class and classified according to the following convention: very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1000 to <1/100), rare (≥1/10,000 to <1/1000), very rare (<1/10,000), or not known (cannot be estimated from the available data). Within each frequency grouping, adverse reactions are presented in decreasing order of seriousness.

System Organ Classification	**Frequency**	**Adverse reaction**
Psychiatric disorders	Uncommon	abnormal dreams
Nervous system disorders	Uncommon	headache, sinus headache, dysgeusia
Eye disorders	Common	eye pain, eye pruritus, conjunctival hyperaemia
	Uncommon	corneal infiltrates, corneal staining, blurred vision, eye irritation, dry eye foreign body sensation in eyes, lacrimation increased, asthenopia, ocular hyperaemia
Cardiac disorders	Not known	tachycardia
Skin and subcutaneous tissue disorders	Uncommon	rash

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in Appendix V.

4.9 Overdose

No specific reactions are to be expected with an ocular overdose of the product.

No data are available in humans regarding overdose by accidental or deliberate ingestion. In case of the deliberate ingestion of the contents of many unit doses of EMADINE, sedative effects may occur and the potential of emedastine to increase the QT interval should be borne in mind and appropriate monitoring and management should be implemented.

5. PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties

Pharmacotherapeutic group: decongestants and antiallergics; other antiallergics. ATC code: S01G X 06.

Emedastine is a potent selective and topically effective histamine H_1 antagonist (K_i = 1.3 nM). *In vitro* examinations of emedastine's affinity for histamine receptors (H_1, H_2, and H_3) demonstrate 10,000-fold selectivity for the H_1 receptor, K_is = 1.3 nM, 49,064 nM and 12, 430 nM, respectively. *In vivo* topical ocular administration of emedastine produces a concentration-dependent inhibition of histamine-stimulated conjunctival vascular permeability. Studies with emedastine have not shown effects on adrenergic, dopaminergic, and serotonin receptors.

5.2 Pharmacokinetic properties

Absorption

Emedastine is absorbed systemically, as are other topically administered drug substances. In a study involving ten normal volunteers dosed bilaterally twice daily for 15 days with EMADINE 0.5 mg/ml eye drops, solution, plasma concentrations of the parent compound were generally below the quantitation limit of the assay (0.3 ng/ml). Samples in which emedastine was quantifiable ranged from 0.30 to 0.49 ng/ml.

The human oral bioavailability of emedastine is approximately 50% and maximum plasma concentrations were achieved within one-two hours after dosing.

Biotransformation

Emedastine is principally metabolised by the liver. The elimination half-life of topical emedastine is ten hours. Approximately 44% of an oral dose is recovered in the urine over 24 hours, with only 3.6% of the dose excreted as parent drug substance. Two primary metabolites, 5-and 6-hydroxyemedastine, are excreted in the urine as both free and conjugated forms. The 5′-oxo analogues of 5-and 6-hydroxyemedastine and the N-oxide are also formed as minor metabolites.

5.3 Preclinical Safety Data

Emedastine difumarate demonstrated low acute toxicity in a number of species by various routes of administration. No clinically significant local or systemic effects were observed in long-term topical ocular studies in rabbits.

Corneal limbal mononuclear cell infiltrates were noted in 1/4 male monkeys treated with 0.5 mg/ml and in 4/4 males and 1/4 females treated with 1.0 mg/ml. Scleral mononuclear cell infiltrates were present in 1/4 males and 1/4 females treated with 0.5 mg/ml and in 2/4 males and 1/4 females treated with 1.0 mg/ml. Mean peak plasma levels were approximately 1 ng/ml and 2 ng/ml for the 0.5 and 1.0 mg/ml treatments respectively.

Emedastine was found to increase the QT interval in dogs; the NOEL corresponds to levels 23 fold higher than those found in patients (7 ng/ml as compared with 0.3 ng/ml, i.e., the limit of detection for emedastine).

Emedastine difumarate was not found to be carcinogenic in studies in mice and rats. Emedastine difumarate was not genotoxic in a standard battery of *in vitro* and *in vivo* genotoxicity assays.

In a teratology study in rats, foetotoxic but not teratogenic effects were observed at the highest dose evaluated (140 mg/kg/day); no effects were observed at a lower level (40 mg/kg/day) which corresponds to an exposure well in excess of that produced by the therapeutic recommended dose. No reproductive toxicity was observed in a study in rabbits.

There was no evidence of impaired fertility or decreased reproductive capacity in rats administered oral dosages of Emedastine difumarate of up to 30 mg/kg/day.

6. PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Trometamol
Sodium chloride
Hypromellose
Hydrochloric acid/sodium hydroxide (to adjust pH)
Purified water

6.2 Incompatibilities

Not applicable.

6.3 Shelf life

2 years.

After first opening a foil pouch: 7 days.

6.4 Special precautions for storage

Do not store above 30°C.

6.5 Nature and content of container

EMADINE is supplied in low density polyethylene single-dose containers which contain 0.35 ml. Five single-dose containers are then presented in a foil pouch.

The following pack sizes are available: 30 x 0.35 ml single-dose containers and 60 x 0.35 ml single-dose containers. Not all pack sizes may be marketed.

6.6 Special precautions for disposal

For single use only; one container is sufficient to treat both eyes. Any unused solution should be discarded immediately after use.

7. MARKETING AUTHORISATION HOLDER

Novartis Europharm Limited
Vista Building
Elm Park, Merrion Road
Dublin 4
Ireland

8. MARKETING AUTHORISATION NUMBERS

EU/1/98/095/003-4

9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

Date of first authorisation: 27 January 1999
Date of latest renewal: 13 January 2009

10. DATE OF REVISION OF THE TEXT

Detailed information on this medicinal product is available on the website of the European Medicines Agency http://www.ema.europa.eu.

ANNEX II

A. MANUFACTURERS RESPONSIBLE FOR BATCH RELEASE

B. CONDITIONS OR RESTRICIONS REGARDING SUPPLY AND USE

C. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION

D. CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT

A. MANUFACTURERS RESPONSIBLE FOR BATCH RELEASE

Names and addresses of the manufacturers responsible for batch release

EMADINE 0.5 mg/ml eye drops, solution
S.A. Alcon-Couvreur N.V.,
Rijksweg 14,
B-2870 Puurs,
Belgium.

Alcon Cusí, S.A.,
Camil Fabra 58,
08320 El Masnou,
Barcelona,
Spain.

EMADINE 0.5 mg/ml eye drops, solution, single-dose container.

S.A. Alcon-Couvreur N.V.,
Rijksweg 14,
B-2870 Puurs,
Belgium.

The printed package leaflet of the medicinal product must state the name and address of the manufacturer responsible for the release of the concerned batch.

B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE

Medicinal product subject to medical prescription

C. OTHER CONDITIONS OR RESTRICTIONS WITH THE MARKETING AUTHORISATION

- **Periodic Safety Update Reports**

The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.

D. CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT

Not applicable.

ANNEX III

LABELLING AND PACKAGE LEAFLET

A. LABELLING

PARTICULARS TO APPEAR ON THE OUTER PACKAGING

BOX OF 1 BOTTLE, 5 ml & 10 ml

1. NAME OF THE MEDICINAL PRODUCT

EMADINE 0.5 mg/ml eye drops, solution
emedastine

2. STATEMENT OF ACTIVE SUBSTANCE

Emedastine 0.5 mg/ml as difumarate

3. LIST OF EXCIPIENTS

Contains: benzalkonium chloride 0.1 mg/ml, trometamol, sodium chloride, hypromellose, hydrochloric acid/sodium hydroxide, purified water.

4. PHARMACEUTICAL FORM AND CONTENTS

Eye drops, solution

1 x 5 ml
1 x 10 ml

5. METHOD AND ROUTE OF ADMINISTRATION

Read the package leaflet before use.
Ocular use

6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN

Keep out of the sight and reach of children.

7. OTHER SPECIAL WARNINGS, IF NECESSARY

8. EXPIRY DATE

EXP
Discard four weeks after first opening.
Opened:

9. SPECIAL STORAGE CONDITIONS

Do not store above 25°C.

10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE

11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

Novartis Europharm Limited
Vista Building
Elm Park, Merrion Road
Dublin 4
Ireland

12. MARKETING AUTHORISATION NUMBERS

EU/1/98/095/001 1 x 5 ml
EU/1/98/095/002 1 x 10 ml

13. BATCH NUMBER

Lot

14. GENERAL CLASSIFICATION FOR SUPPLY

Medicinal product subject to medical prescription.

15. INSTRUCTIONS ON USE

16. INFORMATION IN BRAILLE

Emadine

17. UNIQUE IDENTIFIER – 2D BARCODE

2D barcode carrying the unique identifier included.

18. UNIQUE IDENTIFIER - HUMAN READABLE DATA

PC:
SN:
NN:

MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS

BOTTLE LABEL 5 ml & 10 ml

1. NAME OF THE MEDICINAL PRODUCT AND ROUTE OF ADMINISTRATION

EMADINE 0.5 mg/ml eye drops
emedastine
Ocular use

2. METHOD OF ADMINISTRATION

Read the package leaflet before use.

3. EXPIRY DATE

EXP
Discard four weeks after first opening.
Opened:

4. BATCH NUMBER

Lot

5. CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT

5 ml
10 ml

6 OTHER

PARTICULARS TO APPEAR ON THE OUTER PACKAGING

Carton for 30 x 0.35 ml containers & carton of 60 x 0.35 ml containers

1 NAME OF MEDICINAL PRODUCT

EMADINE 0.5 mg/ml eye drops, solution, single-dose container
emedastine

2 STATEMENT OF ACTIVE SUBSTANCE

Emedastine 0.5 mg/ml as difumarate

3 LIST OF EXCIPIENTS

Contains: trometamol, sodium chloride, hypromellose, hydrochloric acid, sodium hydroxide and purified water.

4 PHARMACEUTICAL FORM AND CONTENTS

Eye drops, solution

0.35 ml x 30
0.35 ml x 60

5 METHOD AND ROUTE OF ADMINISTRATION

Read the package leaflet before use.
Ocular use

6 SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN

Keep out of the sight and reach of children.

7 OTHER SPECIAL WARNINGS, IF NECESSARY

For single use only; one container is sufficient to treat both eyes. Preservative free.

8 EXPIRY DATE

EXP
Discard any unused contents of a single use container immediately after use.
Discard any unused containers one week after first opening pouch.

9 SPECIAL STORAGE CONDITIONS

Do not store above 30°C.

10 SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE

11 NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

Novartis Europharm Limited
Vista Building
Elm Park, Merrion Road
Dublin 4
Ireland

12 MARKETING AUTHORISATION NUMBERS

EU/1/98/095/003	0.35 ml x 30
EU/1/98/095/004	0.35 ml x 60

13 BATCH NUMBER

Lot

14 GENERAL CLASSIFICATION FOR SUPPLY

Medicinal product subject to medical prescription.

15 INSTRUCTIONS ON USE

16. INFORMATION IN BRAILLE

Emadine

17. UNIQUE IDENTIFIER – 2D BARCODE

2D barcode carrying the unique identifier included.

18. UNIQUE IDENTIFIER - HUMAN READABLE DATA

PC:
SN:
NN:

PARTICULARS TO APPEAR ON THE OUTER PACKAGING OR, WHERE THERE IS NO OUTER PACKAGING, ON THE IMMEDIATE PACKAGING

Foil Pouch

1. NAME OF THE MEDICINAL PRODUCT

EMADINE 0.5 mg/ml eye drops, solution, single-dose container
emedastine

2. STATEMENT OF ACTIVE SUBSTANCE

Emedastine 0.5 mg/ml as difumarate

3. LIST OF EXCIPIENTS

Contains: trometamol, sodium chloride, hypromellose, hydrochloric acid, sodium hydroxide and purified water.

4. PHARMACEUTICAL FORM AND CONTENTS

Eye drops, solution

0.35 ml x 5

5. METHOD AND ROUTE OF ADMINISTRATION

Read the package leaflet before use.
Ocular use

6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN

Keep out of the sight and reach of children.

7. OTHER SPECIAL WARNINGS, IF NECESSARY

For single use only; one container is sufficient to treat both eyes. Preservative free.

8. EXPIRY DATE

EXP
Discard any unused contents of a single use container immediately after use.
Discard any unused containers one week after first opening pouch.

9. SPECIAL STORAGE CONDITIONS

Do not store above 30°C.

10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE

11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

Novartis Europharm Limited
Vista Building
Elm Park, Merrion Road
Dublin 4
Ireland

12. MARKETING AUTHORISATION NUMBERS

EU/1/98/095/003	0.35 ml x 30
EU/1/98/095/004	0.35 ml x 60

13. BATCH NUMBER

Lot

14. GENERAL CLASSIFICATION FOR SUPPLY

Medicinal product subject to medical prescription.

15. INSTRUCTIONS ON USE

Tear open pouch at level of cut.

MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS

Single-dose container

1. NAME OF THE MEDICINAL PRODUCT AND ROUTE OF ADMINISTRATION

EMADINE
Ocular use

2. METHOD OF ADMINISTRATION

Read the package leaflet before use.

3. EXPIRY DATE

EXP

4. BATCH NUMBER

Lot

5. CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT

6 OTHER

B. PACKAGE LEAFLET

Package leaflet: Information for the patient

EMADINE 0.5 mg/ml eye drops, solution
emedastine

Read all of this leaflet carefully before you start using this medicine because it contains important information for you.
- Keep this leaflet. You may need to read it again.
- If you have any further questions, ask your doctor or your pharmacist.
- This medicine has been prescribed for you only. Do not pass it on to others. It may harm them even if their signs of illness are the same as yours.
- If you get any of the side effects talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4.

What is in this leaflet

1. What EMADINE is and what it is used for

EMADINE is a medicine for the treatment of seasonal allergic conjunctivitis of the eye (allergic conditions of the eye). It works by reducing the intensity of the allergic reaction.

Allergic conjunctivitis. Some materials (allergens) like pollens, house dust or animal fur may cause allergic reactions resulting in itching, redness as well as swelling of the surface of your eye.

You must talk to a doctor if you do not feel better or if you feel worse.

2. What you need to know before you use EMADINE

Do not use EMADINE
- **if you are allergic** to emedastine or any of the other ingredients of this medicine listed in section 6.

Ask your doctor for advice.

Warning and precautions
- **Do not use EMADINE in children under the age of 3 years.**
- **If you wear contact lenses** please see section ‘EMADINE contains benzalkonium chloride below’.
- **EMADINE is not recommended** for use in patients over 65 years of age, as it has not been studied in clinical trials in this age group.
- **EMADINE is not recommended** for use in patients with kidney or liver problems.

Talk to your doctor or pharmacist before using EMADINE.

Other medicines and EMADINE
Tell your doctor or pharmacist if you are using, have recently used or might use any other medicines.

If you are using other eye drops at the same time as EMADINE, follow the advice at the end of section 3 “How to use EMADINE”.

Pregnancy, breast feeding and fertility
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.

Driving and using machines
You may find that your vision is blurred for a time just after you use EMADINE. Do not drive or use machines until your vision is clear.

EMADINE contains benzalkonium chloride

This medicine contains 0.5 mg or 1 mg benzalkonium chloride in each 5 or 10 ml, which are equivalent to 0.1 mg/ml.

The preservative in EMADINE, benzalkonium chloride, may be absorbed by soft contact lenses and may change the colour of the contact lenses. You should remove contact lenses before using this medicine and put them back 15 minutes afterwards. Benzalkonium chloride may also cause eye irritation, especially if you have dry eyes or disorders of the cornea (the clear layer at the front of the eye). If you feel abnormal eye sensation, stinging or pain in the eye after using this medicine, talk to your doctor.

3. How to use EMADINE

Always use EMADINE exactly as your doctor has told you. You should check with your doctor or pharmacist if you are not sure.

The recommended dose is in adults and children over 3 years: **One drop in the eye, twice a day**.

Always use this medicine exactly as described in this leaflet or as your doctor has told you. Check with your doctor or pharmacist if you are not sure.

Only use the drops in your eyes.

Turn the page for more advice

Now turn over>

3. How to use EMADINE (*continued)*



1



2

The recommended dose
< see side 1

- Get the EMADINE bottle and a mirror.
- Wash your hands.
- Take the bottle and twist off the cap.
- After cap is removed, if tamper evident snap collar is loose, remove before using product.
- Hold the bottle, pointing down, between your thumb and middle finger.

- Tilt your head back. Pull down your eyelid with a clean finger, until there is a ‘pocket’ between the eyelid and your eye. The drop will go in here (picture 1).
- Bring the bottle tip close to the eye. Use the mirror if it helps.
- **Don’t touch your eye or eyelid, surrounding areas or other surfaces with the dropper.** It could infect the drops left in the bottle.
- **Gently press on the base** of the bottle to release one drop of EMADINE at a time.
- **Don’t squeeze the bottle,** it is designed so that just a gentle press on the bottom is needed (picture 2).
- If you use drops in both eyes, repeat the steps for your other eye.
- Put the bottle cap back on firmly immediately after use.

If you accidentally swallow EMADINE or inject it contact a doctor immediately. It may affect your heart rhythm.

If a drop misses your eye, try again.

If you get too much in your eyes, rinse it all out preferably with sterile saline or, if not available, with warm water. Don’t put in any more drops until it’s time for your next regular dose.

If you forget to use EMADINE, use one drop as soon as you remember, and then go back to your normal routine. **Do not use a double dose** to make up for the one missed.

If you are using other eye drops, leave at least 10 minutes between using EMADINE and the other drops. Eye ointments should be used last.

If you have any further questions on the use of this medicine, ask your doctor or pharmacist.

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.

You can carry on taking the drops, unless the effects are serious, If you are worried, talk to your doctor or pharmacist.

Common side effects (may affect up to 1in 10 people)
- Effects in the eye: eye pain, itchy eye, eye redness

Uncommon side effects (may affect up to 1 in 100 people)
- Effects in the eye: corneal disorder, abnormal eye sensation, increased tear production, tired eyes, eye irritation, blurred vision, corneal staining, dry eye.
- General side effects: headache, difficulty sleeping, sinus headache, bad taste, rash

Not Known (frequency cannot be estimated from the available data)
- General side effects: increased heart rate

Reporting of side effects
If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.

5. How to store EMADINE

Keep out of the sight and reach of children.

Do not use EMADINE after the expiry date which is stated on the bottle and box after "EXP". The expiry date refers to the last day of the month.

Do not store above 25°C.

You must throw away the bottle four weeks after you first opened it, to prevent infections. Write down the date you opened each bottle in the space below and in the space on the bottle label and box.

Opened:

Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.

6. Contents of the pack and other information

What EMADINE contains
- The active substance is emadastine 0.5 mg/ml as difumarate.
- The other ingredients are benzalkonium chloride, trometamol; sodium chloride; hypromellose; purified water. Tiny amounts of hydrochloric acid or sodium hydroxide are sometimes added to keep acidity levels (pH levels) normal

What EMADINE looks like and the contents of the pack
EMADINE is a liquid (a solution) supplied in a pack containing a 5 ml or 10 ml plastic (DROP-TAINER) bottle with a screw cap. Not all pack sizes may be marketed.

Marketing authorisation holder
Novartis Europharm Limited
Vista Building
Elm Park, Merrion Road
Dublin 4
Ireland

Manufacturer
S.A. Alcon-Couvreur N.V.,
Rijksweg 14,
B-2870 Puurs,
Belgium

Manufacturer
Alcon Cusí, S.A.,
Camil Fabra 58,
08320 El Masnou,
Spain

For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:

België/Belgique/Belgien
Novartis Pharma N.V.
Tél/Tel: +32 2 246 16 11

Lietuva
SIA „Novartis Baltics" Lietuvos filialas
Tel: +370 5 269 16 50

България
Novartis Bulgaria EOOD
Тел.: +359 2 489 98 28

Česká republika
Novartis s.r.o.
Tel: +420 225 775 111

Danmark
Novartis Healthcare A/S
Tlf: +45 39 16 84 00

Deutschland
Novartis Pharma GmbH
Tel: +49 911 273 0

Eesti
SIA Novartis Baltics Eesti filiaal
Tel: +372 66 30 810

Ελλάδα
Novartis (Hellas) A.E.B.E.
Τηλ: +30 210 281 17 12

España
Novartis Farmacéutica, S.A.
Tel: +34 93 306 42 00

France
Novartis Pharma S.A.S.
Tél: +33 1 55 47 66 00

Hrvatska
Novartis Hrvatska d.o.o.
Tel. +385 1 6274 220

Ireland
Novartis Ireland Limited
Tel: +353 1 260 12 55

Ísland
Vistor hf.
Sími: +354 535 7000

Italia
Novartis Farma S.p.A.
Tel: +39 02 96 54 1

Κύπρος
Novartis Pharma Services Inc.
Τηλ: +357 22 690 690

Latvija
SIA "Novartis Baltics"
Tel: +371 67 887 070

Luxembourg/Luxemburg
Novartis Pharma N.V.
Tél/Tel: +32 2 246 16 11

Magyarország
Novartis Hungária Kft.
Tel.: +36 1 457 65 00

Malta
Novartis Pharma Services Inc.
Tel: +356 2122 2872

Nederland
Novartis Pharma B.V.
Tel: +31 26 37 82 111

Norge
Novartis Norge AS
Tlf: +47 23 05 20 00

Österreich
Novartis Pharma GmbH
Tel: +43 1 86 6570

Polska
Novartis Poland Sp. z o.o.
Tel.: +48 22 375 4888

Portugal
Novartis Farma - Produtos Farmacêuticos, S.A.
Tel: +351 21 000 8600

România
Novartis Pharma Services Romania SRL
Tel: +40 21 31299 01

Slovenija
Novartis Pharma Services Inc.
Tel: +386 1 300 75 50

Slovenská republika
Novartis Slovakia s.r.o.
Tel: + 421 2 5542 5439

Suomi/Finland
Novartis Finland Oy
Puh/Tel: +358 (0)10 6133 200

Sverige
Novartis Sverige AB
Tel: +46 8 732 32 00

United Kingdom
Novartis Pharmaceuticals UK Ltd.
Tel: +44 1276 698370

This leaflet was last revised in

Other sources of information
Detailed information on this medicine is available on the European Medicines Agency website: http://www.ema.europa.eu.

Package leaflet: Information for the patient

EMADINE 0.5 mg/ml eye drops, solution, single-dose container
emedastine

Read all of this leaflet carefully before you start using this medicine because it contains important information for you.
- Keep this leaflet. You may need to read it again.
- If you have any further questions, ask your doctor or your pharmacist.
- This medicine has been prescribed for you only. Do not pass it on to others. It may harm them even if their signs of illness are the same as yours.
- If you get any of the side effects talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4.

What is in this leaflet

1. What EMADINE is and what it is used for

EMADINE is a medicine for the treatment of seasonal allergic conjunctivitis of the eye (allergic conditions of the eye). It works by reducing the intensity of the allergic reaction.

Allergic conjunctivitis. Some materials (allergens) like pollens, house dust or animal fur may cause allergic reactions resulting in itching, redness as well as swelling of the surface of your eye. You must talk to a doctor if you do not feel better or if you feel worse.

2. What you need to know before you use EMADINE

Do not use EMADINE
- **if you are allergic** to emedastine or any of the other ingredients of this medicine listed in section 6.

Ask your doctor for advice.

Warning and precautions
- **Do not use EMADINE in children under the age of 3 years.**
- **EMADINE is not recommended** for use in patients over 65 years of age, as it has not been studied in clinical trials in this age group.
- **EMADINE is not recommended** for use in patients with kidney or liver problems.

Talk to your doctor or pharmacist before using EMADINE.

Other medicines and EMADINE.
Tell your doctor or pharmacist if you are using, have recently used or might use any other medicines.

If you are using other eye drops at the same time as EMADINE, follow the advice at the end of section 3 (How to use EMADINE).

Pregnancy, breast feeding and fertility
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.

Driving and using machines
You may find that your vision is blurred for a time just after you use EMADINE. Do not drive or use machines until your vision is clear.

3. How to use EMADINE

Always use EMADINE exactly as your doctor has told you. You should check with your doctor or pharmacist if you are not sure.

The recommended dose is in adults and children over 3 years: **One drop in the eye, twice a day**.

Always use this medicine exactly as described in this leaflet or as your doctor has told you. Check with your doctor or pharmacist if you are not sure.

Only use the drops in your eyes.

Turn the page for more advice

Now turn over>

3. How to use EMADINE (*continued)*



1



2

3

The recommended dose
< see side 1

Do not use a container you've already opened. Do not use any sealed containers from a foil wrapper that was opened more than a week ago.

- Tear off the foil wrapper and take out the strip of 5 containers.
- **Do not use if the solution is cloudy or has bits in it.**
- Hold the strip with the long flat end uppermost and separate off one container by pulling it towards you while holding the others firm. You will need to snap it apart where it joins the others (picture 1).
- Keep the single container out. Put the others back in the foil wrapper.
- Make sure you have a mirror handy and wash your hands.
- Hold the long flat end of the container between your thumb and forefinger and open it by twisting off the other end (picture 2).
- Tilt your head back. Pull down your eyelid with a clean finger, until there is a 'pocket' between the eyelid and your eye. The drop will go in here.
- Hold the container between your thumb and fingers with the open end pointing down.
- Bring the container tip close to the eye. Use the mirror if it helps.

- **Don’t touch your eye or eyelid, surrounding areas or other surfaces with the container tip.** It could infect the drops.
- Gently squeeze the container to release one drop into the pocket between the eyelid and eye (picture 3).
- **If your doctor has told you to use drops in both eyes, repeat the steps for your other eye-using the same container.**
- **Throw away the container and any leftover solution at once.**
- **Throw away any unused containers one week after opening the foil wrapper-even if the containers are still sealed.**

If you accidentally swallow EMADINE or inject it contact a doctor immediately. It may affect your heart rhythm.

If a drop misses your eye, try again.

If you get too much in your eyes, rinse it all out preferably with sterile saline or, if not available, with warm water. Don’t put in any more drops until it’s time for your next regular dose.

If you forget to use EMADINE use one drop as soon as you remember, and then go back to your normal routine. **Do not use a double dose** to make up for the one missed.

If you are using other eye drops, leave at least 10 minutes between using EMADINE and the other drops. Eye ointments should be used last.

If you have any further questions on the use of this medicine, ask your doctor or pharmacist.

4. Possible side effects

Like all medicines this medicine can cause side effects although not everybody gets them.

You can carry on taking the drops, unless the effects are serious. If you are worried, talk to your doctor or pharmacist.

Common side effects (may affect up to 1 in 10 people)
- Effects in the eye: eye pain, itchy eye, eye redness

Uncommon side effects (may affect up to 1 in 100 people)
- Effects in the eye: corneal disorder, abnormal eye sensation, increased tear production, tired eyes, eye irritation, blurred vision, corneal staining, dry eye.
- General side effects: headache, difficulty sleeping, sinus headache, bad taste, rash

Not Known (frequency cannot be estimated from the available data)
- General side effects: increased heart rate

Reporting of side effects
If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.

5. How to store EMADINE

Keep out of the sight and reach of children

Do not use EMADINE after the expiry date which is stated on the bottle and box after "EXP". The expiry date refers to the last day of the month.

Do not store above 30°C.

You must throw away the container as soon as you have used it. Once the foil wrapper has been opened any unused containers must be thrown away one week after you first opened it.

Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the enviroment.

6 Contents of the pack and other information

What EMADINE contains
- The active substance is emedastine 0.5 mg/ml as difumarate.
- The other ingredients are trometamol; sodium chloride; hypromellose; purified water. Tiny amounts of hydrochloric acid or sodium hydroxide are sometimes added to keep acidity levels (pH levels) normal.

What EMADINE looks like and the contents of the pack
EMADINE is a liquid (a solution) supplied in single-dose plastic containers which contain 0.35 ml. Five single-dose containers are provided in a pouch. EMADINE is supplied in packs containing 30 or 60 units. Not all pack sizes may be marketed.

Marketing authorisation holder
Novartis Europharm Limited
Vista Building
Elm Park, Merrion Road
Dublin 4
Ireland

Manufacturer
S.A. Alcon-Couvreur N.V.,
Rijksweg 14,
B-2870 Puurs,
Belgium

For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:

België/Belgique/Belgien
Novartis Pharma N.V.
Tél/Tel: +32 2 246 16 11

България
Novartis Bulgaria EOOD
Тел.: +359 2 489 98 28

Česká republika
Novartis s.r.o.
Tel: +420 225 775 111

Lietuva
SIA „Novartis Baltics" Lietuvos filialas
Tel: +370 5 269 16 50

Luxembourg/Luxemburg
Novartis Pharma N.V.
Tél/Tel: +32 2 246 16 11

Magyarország
Novartis Hungária Kft.
Tel.: +36 1 457 65 00

Danmark
Novartis Healthcare A/S
Tlf: +45 39 16 84 00

Deutschland
Novartis Pharma GmbH
Tel: +49 911 273 0

Eesti
SIA Novartis Baltics Eesti filiaal
Tel: +372 66 30 810

Ελλάδα
Novartis (Hellas) A.E.B.E.
Τηλ: +30 210 281 17 12

España
Novartis Farmacéutica, S.A.
Tel: +34 93 306 42 00

France
Novartis Pharma S.A.S.
Tél: +33 1 55 47 66 00

Hrvatska
Novartis Hrvatska d.o.o.
Tel. +385 1 6274 220

Ireland
Novartis Ireland Limited
Tel: +353 1 260 12 55

Ísland
Vistor hf.
Sími: +354 535 7000

Italia
Novartis Farma S.p.A.
Tel: +39 02 96 54 1

Κύπρος
Novartis Pharma Services Inc.
Τηλ: +357 22 690 690

Latvija
SIA "Novartis Baltics"
Tel: +371 67 887 070

Malta
Novartis Pharma Services Inc.
Tel: +356 2122 2872

Nederland
Novartis Pharma B.V.
Tel: +31 26 37 82 111

Norge
Novartis Norge AS
Tlf: +47 23 05 20 00

Österreich
Novartis Pharma GmbH
Tel: +43 1 86 6570

Polska
Novartis Poland Sp. z o.o.
Tel.: +48 22 375 4888

Portugal
Novartis Farma - Produtos Farmacêuticos, S.A.
Tel: +351 21 000 8600

România
Novartis Pharma Services Romania SRL
Tel: +40 21 31299 01

Slovenija
Novartis Pharma Services Inc.
Tel: +386 1 300 75 50

Slovenská republika
Novartis Slovakia s.r.o.
Tel: + 421 2 5542 5439

Suomi/Finland
Novartis Finland Oy
Puh/Tel: +358 (0)10 6133 200

Sverige
Novartis Sverige AB
Tel: +46 8 732 32 00

United Kingdom
Novartis Pharmaceuticals UK Ltd.
Tel: +44 1276 698370

This leaflet was last revised in

Other sources of information
Detailed information on this medicine is available on the European Medicines Agency website: http://www.ema.europa.eu